Objective:To summarize the best evidence for anxiety and depression management in adults with coronary heart disease (CHD).Methods:Evidence regarding anxiety and depression management of adults with CHD was retrieved from the British Medical Journal best practice, UpToDate, Guidelines International Network, National Institute for Health and Care Excellence, Scottish Intercollegiate Guideline Network, Registered Nurses Association of Ontario, Cochrane Library, the Joanna Briggs Institute (JBI), PubMed, Embase, Medline, Web of Science, China National Knowledge Infrastructure, and WanFang Data. These publications included guidelines, systematic reviews, expert consensus, and evidence summaries. The data retrieval time was from the establishment of the databases to September 13, 2021. The search terms included coronary heart disease, psychology, anxiety and depression, and the data was sorted on September 14-23, 2021. Two researchers evaluated the quality of the literature and extracted data independently according to both AGREE Ⅱ and the evaluation tools of the JBI evidence-based healthcare center. The evidence level was graded by using the evidence preliminary classification system and the evidence recommendation level system of the JBI evidence-based healthcare center. The recommended strength of the evidence was determined with the guidance of JBI′s evidence structure and the discussion within the research group and expert opinions, and then the best evidence for anxiety and depression management in adults with CHD were extracted, summarized and analyzed. Results:A total of 22 articleswere included, including 5 clinical guidelines, 14 systematic reviews, 2 expert consensuses and 1 evidence summary. Three articles of the guidelines were graded B with the up-mentioned recommendtation standard, and the other two were graded A. In the systematic reviews, five articles were rated as grade B, the other nine articles as grade A, and 95% of the items were evaluated as “yes”. The evaluation results of all items in the expert consensuses were “yes”, and the quality grade was A. The evidence summary involved 32 pieces of best evidence regarding five aspects (mental health management mode, risk factor assessment and prevention, psychological problem identification and screening, psychological adjustment and intervention, drug treatment), of which 60% were class 1 evidence, and 34% were recommended with strength A.Conclusions:The overall quality of the literature and the level of evidence regarding anxiety and depression management in adults with CHD are high. The key to anxiety and depression management in these patients is innovating the mode of mental health management and implementing effective risk factor assessment and prevention, psychological problem identification and screening, psychological adjustment and intervention, and drug treatment.

Objective To compare the changes of the Chinese Materia Medica resources(CMMR)in Sichuan based on the data of the 3rd Chinese Materia Medica Resource Inventory(CMMRI,1983-1986)and the 4th CMMRI(2011-2022).Methods Using new techniques,after field investigation,collection and identification of the specimens of the animals,plants and minerals.The data of the CMMR in Sichuan found in the 4th CMMRI were analysed and compared with the data of 3rd CMMRI.Results ①9055 species of CMMR were found in Sichuan during the 4th CMMRI,including 8272 species of medicinal plants,745 species of medicinal animals and 38 species of medicinal minerals.Compared with the 3rd CMMRI,the number of CMMR found in Sichuan have greatly increased.The number of medicinal plants increased 5018 species,the number of medicinal animals increased 637 species and the number of medicinal minerals increased 5 species,too.②The medicinal plants is the main part of the CMMR,and the higher plants(7774 species)has the absolute advantage of the CMMR.The top 20 families which have plenty of plant species include Compositae,Rosaceae,Leguminosae,Ranunculaceae,etc.③ Based on the data of the CMMR of the 183 counties in Sichuan,the reserves of 235 species of wild CMMR in Sichuan is about 36.72 million ton.There were 49 CMMR which have reserves beyond 100 thousand tons,such as Arisaematis rhizoma,Epimedii folium,Cimicifugae rhizoma,Acori tatarinowii rhizoma,Gentianae macrophyllae radix,Polygoni multiflori radix etc.④In 2021,there were 215 species of CMMR cultivated in Sichuan,the main species were Aurantii fructus,Chuanxiong rhizoma,Polygonati rhizome,Salviae miltiorrhizae radix et rhizome.The planting area was 8.17 million and the production was 1.26 million ton.⑤All 183 countries were found CMMR,the number of the species of CMMR in 30 countries exceeded 800,including 16 countries which had more than 1000 kinds of CMMR,such as Emeishan,Hongya,Muli etc.The total types of the CMMR(up 118.31%),the reserves of the wild CMMR(up 119 times)and the number of the counties(up 3 times)which had plenty of CMMR,showed a marked increase over the 3rd CMMRI.8 new species were found in the the 4th CMMRI,such as Codonopsis atriplicifolia,Tongoloa tagongensis,Allium xinlongense,etc.Conclusion The species,the reserves of the CMMR and the resource rich countries in Sichuan are the top 3 in China and Sichuan is worthy of the title of"Hometown of Traditional Chinese Medicine".The compositions and types of the family,genus and species of the CMMR in Sichuan have significantly increased.The basic information of the CMR in Sichuan was clearly found out during the 4th CMMRI,and beneficial for the sustainable development and utilization of the CMMR in Sichuan.